Financial news, mergers and acquisitions, partnerships, and alliances.
The Seattle-based immune sequencing firm will not receive any proceeds from the sale of the shares.
Formerly called OncoCell MDx, the Royal Oak, Michigan-based firm aims to complete a validation study for the prostate cancer risk assay within the next two months.
The company has developed a proof-of-concept single-pore sensor that it anticipates integrating into a prototype testing platform this year.
The reagent is used for the detection of cytokeratin 19 mRNA in surgically removed sentinel lymph nodes in order to diagnose lymph node metastasis.
Abbott said the increase in diagnostics revenue was driven by adoption of the company's Alinity family of diagnostic instruments.
